International Randomized Trial to Find the Best Way to Start Peritoneal Dialysis for Adults with Kidney Failure Co-designed with Patients to Improve Quality of Life and Treatment Safety

What this Trial Is About

This research aims to find the best way to start patients with kidney failure on peritoneal dialysis PD, a life-saving treatment done at home. The trial compares the usual full dose PD, prescribed 24 hours a day, 7 days a week, to a lower dose that increases over time, called incremental PD. The study is designed to see if starting with lower doses can maintain quality of life, reduce treatment burden, and be safer and more cost-effective. Participants are randomly assigned to either the incremental PD group, which uses a goal-directed prescription with fewer exchanges per week until an increase is needed, or the full dose PD group, which uses continuous treatment every day. The trial is international, multicenter, and open-label, involving many experts and consumers with PD experience to guide the design. During the study, participants quality of life, kidney function, and safety outcomes such as serious adverse events and hospitalizations will be monitored for up to 18 months. The main focus is on quality of life measured over the first 6 months of treatment. Researchers will track various health events and dialysis complications to assess the impact of the PD dosing strategies. The study may lead to more personalized and less burdensome dialysis treatments worldwide.

STarting incrEmental Prescription of Peritoneal Dialysis